Cerenome Appoints Director Ron Andrews as Chief Business Officer
Key Highlights
- ➤Cerenome (CNSY) appoints Ron Andrews chief business officer in newly created position
- ➤Andrews will lead business development, commercial strategy, CNSide adoption, and strategic partnerships
- ➤Andrews helped companies raise more than $600 million and achieve strategic exits totaling more than $15 billion
- ➤Clarient, led by Andrews, was acquired by GE Healthcare for $587 million
Expert Statements
Marc H. Hedrick, M.D., President and Chief Executive Officer of Cerenome
“Ronnie has extensive experience translating diagnostic technologies into commercial success, along with a deep understanding of the clinical, reimbursement, and operational requirements that drive adoption”
Marc H. Hedrick, M.D., President and Chief Executive Officer of Cerenome
“Through his service on our Board, he is well-versed in our strategy and the value of CNSide. His addition to our executive team strengthens our ability to expand our diagnostics business and pursue partnerships that support our integrated CNS oncology platform.”
Ron “Ronnie” Andrews, Chief Business Officer and Director of Cerenome
“My career has featured an unwavering commitment to the democratization of diagnostic technologies, empowering community oncologists and pathologists with the tools they need for precise, timely patient care”
Ron “Ronnie” Andrews, Chief Business Officer and Director of Cerenome
“CNSide addresses an important need in the detection and longitudinal monitoring of CNS cancers, and the opportunity to broaden its use in clinical practice is clear and meaningful.”
Ron “Ronnie” Andrews, Chief Business Officer and Director of Cerenome
“I look forward to working with the Cerenome team to build commercial relationships, strategically expand our industry-leading CNS testing platform and advance the Company’s growth strategy.”
HOUSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence, today announced the appointment of Ron “Ronnie” Andrews as Chief Business Officer, a newly created position. Mr. Andrews will continue to serve on the Company’s Board of Directors.
In his new role, Mr. Andrews will focus on advancing Cerenome’s business development and commercial strategy, with an emphasis on expanding adoption of the CNSide(®) Diagnostics platform and developing strategic partnerships. He brings more than 35 years of diagnostics industry leadership experience, helping companies raise more than $600 million in capital and contributing to strategic exits totaling more than $15 billion.
Get started
Create a free account to read the full story.